nach oben

Erschienen in:

31.10.2017 | Original Article

Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells

verfasst von: Na Li, Jianing Wang, Na Zhang, Mengwei Zhuang, Zhaoyun Zong, Jiahuan Zou, Guosheng Li, Xiaoyan Wang, Huaiyu Zhou, Lining Zhang, Yongyu Shi

Erschienen in: Cancer Immunology, Immunotherapy | Ausgabe 2/2018

Einloggen, um Zugang zu erhalten

Abstract

Clinical benefit from immunotherapy of B7-H1/PD-1 checkpoint blockade indicates that it is important to understand the regulatory mechanism of B7-H1 expression in cancer cells. As an adaptive response to the endogenous antitumor immunity, B7-H1 expression is up-regulated in HCC cells. B7-H1 expression is induced mainly by IFN-γ released from tumor-infiltrating T cells in HCC. In addition, HCC is a prototype of inflammation-related cancer and TNF-α is a critical component of inflammatory microenvironment of HCC. In the present study, we asked whether TNF-α can promote the expression of B7-H1 induced by IFN-γ in HCC cells. We found that JAK/STAT1/IRF1 was the primary pathway responsible for induction of B7-H1 expression by IFN-γ in human HCC cell lines. TNF-α and IFN-γ synergistically induced the expression of B7-H1 in the HCC cells. Moreover, the mechanism of the synergy was that TNF-α enhanced IFN-γ signaling by upregulating the expression of IFN-γ receptors. Furthermore, B7-H1 expression induced synergistically by TNF-α and IFN-γ in murine HCC cells facilitated tumor growth in vivo. Our findings suggest that TNF-α may enhance the adaptive immune resistance mediated by IFN-γ-induced B7-H1 in HCC cells.

Nur mit Berechtigung zugänglich

Chen L, Han X (2015) Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future. J Clin Investig 125(9):3384–3391. https://doi.org/10.1172/jci80011 CrossRefPubMedPubMedCentral

Calderaro J, Rousseau B, Amaddeo G, Mercey M, Charpy C, Costentin C, Luciani A, Zafrani ES, Laurent A, Azoulay D, Lafdil F, Pawlotsky JM (2016) Programmed death ligand 1 expression in hepatocellular carcinoma: relationship with clinical and pathological features. Hepatology 64(6):2038–2046. https://doi.org/10.1002/hep.28710 CrossRefPubMed

Zou W, Wolchok JD, Chen L (2016) PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci Transl Med 8(328):1–14. https://doi.org/10.1126/scitranslmed.aad7118 CrossRef

Morales-Kastresana A, Sanmamed MF, Rodriguez I, Palazon A, Martinez-Forero I, Labiano S, Hervas-Stubbs S, Sangro B, Ochoa C, Rouzaut A, Azpilikueta A, Bolanos E, Jure-Kunkel M, Gutgemann I, Melero I (2013) Combined immunostimulatory monoclonal antibodies extend survival in an aggressive transgenic hepatocellular carcinoma mouse model. Clin Cancer Res 19(22):6151–6162. https://doi.org/10.1158/1078-0432.CCR-13-1189 CrossRefPubMed

Wang Y, Li H, Liang Q, Liu B, Mei X, Ma Y (2015) Combinatorial immunotherapy of sorafenib and blockade of programmed death-ligand 1 induces effective natural killer cell responses against hepatocellular carcinoma. Tumour Biol 36(3):1561–1566. https://doi.org/10.1007/s13277-014-2722-2 CrossRefPubMed

Harding JJ, El Dika I, Abou-Alfa GK (2016) Immunotherapy in hepatocellular carcinoma: primed to make a difference? Cancer 122(3):367–377. https://doi.org/10.1002/cncr.29769 CrossRefPubMed

Truong P, Rahal A, Kallail KJ (2016) Metastatic hepatocellular carcinoma responsive to pembrolizumab. Cureus 8(6):e631. https://doi.org/10.7759/cureus.631 PubMedPubMedCentral

Sanmamed MF, Chen L (2014) Inducible expression of B7-H1 (PD-L1) and its selective role in tumor site immune modulation. Cancer J 20(4):256–261. https://doi.org/10.1097/PPO.0000000000000061 CrossRefPubMedPubMedCentral

Xie QK, Zhao YJ, Pan T, Lyu N, Mu LW, Li SL, Shi MD, Zhang ZF, Zhou PH, Zhao M (2016) Programmed death ligand 1 as an indicator of pre-existing adaptive immune responses in human hepatocellular carcinoma. Oncoimmunology 5(7):e1181252. https://doi.org/10.1080/2162402X.2016.1181252 CrossRefPubMedPubMedCentral

10.

Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJM, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515(7528):568–571. https://doi.org/10.1038/nature13954 CrossRefPubMedPubMedCentral

11.

Concha-Benavente F, Srivastava RM, Trivedi S, Lei Y, Chandran U, Seethala RR, Freeman GJ, Ferris RL (2016) Identification of the cell-intrinsic and -extrinsic pathways downstream of EGFR and IFNgamma that induce PD-L1 expression in head and neck cancer. Cancer Res 76(5):1031–1043. https://doi.org/10.1158/0008-5472.CAN-15-2001 CrossRefPubMed

12.

Doi T, Ishikawa T, Okayama T, Oka K, Mizushima K, Yasuda T, Sakamoto N, Katada K, Kamada K, Uchiyama K, Handa O, Takagi T, Naito Y, Itoh Y (2017) The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. Oncol Rep 37(3):1545–1554. https://doi.org/10.3892/or.2017.5399 CrossRefPubMed

13.

Chia CS, Ban K, Ithnin H, Singh H, Krishnan R, Mokhtar S, Malihan N, Seow HF (2002) Expression of interleukin-18, interferon-gamma and interleukin-10 in hepatocellular carcinoma. Immunol Lett 84(3):163–172CrossRefPubMed

14.

Qiu FB, Wu LQ, Lu Y, Zhang S, Zhang BY (2007) Predominant expression of Th1-type cytokines in primary hepatic cancer and adjacent liver tissues. Hepatobiliary Pancreat Dis Int 6(1):63–66PubMed

15.

Nagao M, Nakajima Y, Kanehiro H, Hisanaga M, Aomatsu Y, Ko S, Tatekawa Y, Ikeda N, Kanokogi H, Urizono Y, Kobayashi T, Shibaji T, Kanamura T, Ogawa S, Nakano H (2000) The impact of interferon gamma receptor expression on the mechanism of escape from host immune surveillance in hepatocellular carcinoma. Hepatology 32(3):491–500. https://doi.org/10.1053/jhep.2000.16470 CrossRefPubMed

16.

Karin M, Dhar D (2016) Liver carcinogenesis: from naughty chemicals to soothing fat and the surprising role of NRF2. Carcinogenesis 37(6):541–546. https://doi.org/10.1093/carcin/bgw060 CrossRefPubMedPubMedCentral

17.

Grivennikov SI, Karin M (2011) Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage. Ann Rheum Dis 70(Suppl 1):i104–i108. https://doi.org/10.1136/ard.2010.140145 CrossRefPubMed

18.

Aroucha DC, do Carmo RF, Moura P, Silva JL, Vasconcelos LR, Cavalcanti MS, Muniz MT, Aroucha ML, Siqueira ER, Cahu GG, Pereira LM, Coelho MR (2013) High tumor necrosis factor-alpha/interleukin-10 ratio is associated with hepatocellular carcinoma in patients with chronic hepatitis C. Cytokine 62(3):421–425. https://doi.org/10.1016/j.cyto.2013.03.024 CrossRefPubMed

19.

Park EJ, Lee JH, Yu GY, He G, Ali SR, Holzer RG, Osterreicher CH, Takahashi H, Karin M (2010) Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 140(2):197–208. https://doi.org/10.1016/j.cell.2009.12.052 CrossRefPubMedPubMedCentral

20.

Pikarsky E, Porat RM, Stein I, Abramovitch R, Amit S, Kasem S, Gutkovich-Pyest E, Urieli-Shoval S, Galun E, Ben-Neriah Y (2004) NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 431(7007):461–466. https://doi.org/10.1038/nature02924 CrossRefPubMed

21.

Schmittgen TD, Livak KJ (2008) Analyzing real-time PCR data by the comparative CT method. Nat Protoc 3(6):1101–1108. https://doi.org/10.1038/nprot.2008.73 CrossRefPubMed

22.

Schönberger S, Okpanyi V, Calaminus G, Heikaus S, Leuschner I, Nicholson JC, Stoecklein NH, Schneider DT, Borkhardt A (2013) EPCAM-A novel molecular target for the treatment of pediatric and adult germ cell tumors. Genes Chromosom Cancer 52(1):24–32. https://doi.org/10.1002/gcc.22002 CrossRefPubMed

23.

Gough DJ, Levy DE, Johnstone RW, Clarke CJ (2008) IFNgamma signaling-does it mean JAK-STAT? Cytokine Growth Factor Rev 19(5–6):383–394. https://doi.org/10.1016/j.cytogfr.2008.08.004 CrossRefPubMed

24.

Wang H, Wang X, Li X, Fan Y, Li G, Guo C, Zhu F, Zhang L, Shi Y (2014) CD68(+)HLA-DR(+) M1-like macrophages promote motility of HCC cells via NF-kappaB/FAK pathway. Cancer Lett 345(1):91–99. https://doi.org/10.1016/j.canlet.2013.11.013 CrossRefPubMed

25.

Lee SJ, Jang BC, Lee SW, Yang YI, Suh SI, Park YM, Oh S, Shin JG, Yao S, Chen L, Choi IH (2006) Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN-gamma-induced upregulation of B7-H1 (CD274). FEBS Lett 580(3):755–762. https://doi.org/10.1016/j.febslet.2005.12.093 CrossRefPubMed

26.

Gong AY, Zhou R, Hu G, Li X, Splinter PL, O’Hara SP, LaRusso NF, Soukup GA, Dong H, Chen XM (2009) MicroRNA-513 regulates B7-H1 translation and is involved in IFN-gamma-induced B7-H1 expression in cholangiocytes. J Immunol 182(3):1325–1333CrossRefPubMedPubMedCentral

27.

Liu J, Hamrouni A, Wolowiec D, Coiteux V, Kuliczkowski K, Hetuin D, Saudemont A, Quesnel B (2007) Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway. Blood 110(1):296–304. https://doi.org/10.1182/blood-2006-10-051482 CrossRefPubMed

28.

Gu X, Wang Y, Xiang J, Chen Z, Wang L, Lu L, Qian S (2013) Interferon- gamma triggers hepatic stellate cell-mediated immune regulation through MEK/ERK signaling pathway. Clin Dev Immunol 2013:389807. https://doi.org/10.1155/2013/389807 PubMedPubMedCentral

29.

Chen J, Feng Y, Lu L, Wang H, Dai L, Li Y, Zhang P (2012) Interferon-gamma-induced PD-L1 surface expression on human oral squamous carcinoma via PKD2 signal pathway. Immunobiology 217(4):385–393. https://doi.org/10.1016/j.imbio.2011.10.016 CrossRefPubMed

30.

Gowrishankar K, Gunatilake D, Gallagher SJ, Tiffen J, Rizos H, Hersey P (2015) Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-kappaB. PLoS One 10(4):e0123410. https://doi.org/10.1371/journal.pone.0123410 CrossRefPubMedPubMedCentral

31.

Lee SK, Seo SH, Kim BS, Kim CD, Lee JH, Kang JS, Maeng PJ, Lim JS (2005) IFN-gamma regulates the expression of B7-H1 in dermal fibroblast cells. J Dermatol Sci 40(2):95–103. https://doi.org/10.1016/j.jdermsci.2005.06.008 CrossRefPubMed

32.

He G, Karin M (2011) NF-kappaB and STAT3—key players in liver inflammation and cancer. Cell Res 21(1):159–168. https://doi.org/10.1038/cr.2010.183 CrossRefPubMed

33.

Wölfle SJ, Strebovsky J, Bartz H, Sähr A, Arnold C, Kaiser C, Dalpke AH, Heeg K (2011) PD-L1 expression on tolerogenic APCs is controlled by STAT-3. Eur J Immunol 41(2):413–424. https://doi.org/10.1002/eji.201040979 CrossRefPubMed

34.

Carbotti G, Barisione G, Airoldi I, Mezzanzanica D, Bagnoli M, Ferrero S, Petretto A, Fabbi M, Ferrini S (2015) IL-27 induces the expression of IDO and PD-L1 in human cancer cells. Oncotarget 6(41):43267–43280. https://doi.org/10.18632/oncotarget.6530 CrossRefPubMedPubMedCentral

35.

Shirey KA, Jung JY, Maeder GS, Carlin JM (2006) Upregulation of IFN-gamma receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells. J Interferon Cytokine Res 26(1):53–62. https://doi.org/10.1089/jir.2006.26.53 CrossRefPubMedPubMedCentral

36.

Robinson CM, Hale PT, Carlin JM (2006) NF-kappa B activation contributes to indoleamine dioxygenase transcriptional synergy induced by IFN-gamma and tumor necrosis factor-alpha. Cytokine 35(1–2):53–61. https://doi.org/10.1016/j.cyto.2006.07.007 CrossRefPubMed

37.

de Kleijn S, Langereis JD, Leentjens J, Kox M, Netea MG, Koenderman L, Ferwerda G, Pickkers P, Hermans PW (2013) IFN-gamma-stimulated neutrophils suppress lymphocyte proliferation through expression of PD-L1. PLoS One 8(8):e72249. https://doi.org/10.1371/journal.pone.0072249 CrossRefPubMedPubMedCentral

38.

Garcia-Diaz A, Shin DS, Moreno BH, Saco J, Escuin-Ordinas H, Rodriguez GA, Zaretsky JM, Sun L, Hugo W, Wang X, Parisi G, Saus CP, Torrejon DY, Graeber TG, Comin-Anduix B, Hu-Lieskovan S, Damoiseaux R, Lo RS, Ribas A (2017) Interferon receptor signaling pathways regulating PD-L1 and PD-L2 expression. Cell Rep 19(6):1189–1201. https://doi.org/10.1016/j.celrep.2017.04.031 CrossRefPubMed

39.

Chen X, Baumel M, Mannel DN, Howard OM, Oppenheim JJ (2007) Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+ CD25+ T regulatory cells. J Immunol 179(1):154–161CrossRefPubMed

40.

Wajant H, Pfizenmaier K, Scheurich P (2003) Tumor necrosis factor signaling. Cell Death Differ 10(1):45–65. https://doi.org/10.1038/sj.cdd.4401189 CrossRefPubMed

41.

Fischer R, Kontermann R, Maier O (2015) Targeting sTNF/TNFR1 signaling as a new therapeutic strategy. Antibodies 4(1):48–70. https://doi.org/10.3390/antib4010048 CrossRef

42.

Noman MZ, Desantis G, Janji B, Hasmim M, Karray S, Dessen P, Bronte V, Chouaib S (2014) PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSC-mediated T cell activation. J Exp Med 211(5):781–790. https://doi.org/10.1084/jem.20131916 CrossRefPubMedPubMedCentral

43.

Andorsky DJ, Yamada RE, Said J, Pinkus GS, Betting DJ, Timmerman JM (2011) Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res 17(13):4232–4244. https://doi.org/10.1158/1078-0432.CCR-10-2660 CrossRefPubMed

Titel: Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells
verfasst von: Na Li
Jianing Wang
Na Zhang
Mengwei Zhuang
Zhaoyun Zong
Jiahuan Zou
Guosheng Li
Xiaoyan Wang
Huaiyu Zhou
Lining Zhang
Yongyu Shi
Publikationsdatum: 31.10.2017
Verlag: Springer Berlin Heidelberg
Erschienen in: Cancer Immunology, Immunotherapy / Ausgabe 2/2018
Print ISSN: 0340-7004
Elektronische ISSN: 1432-0851
DOI: https://doi.org/10.1007/s00262-017-2086-8

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Cross-talk between TNF-α and IFN-γ signaling in induction of B7-H1 expression in hepatocellular carcinoma cells

Abstract

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2018

NY-ESO-1- and survivin-specific T-cell responses in the peripheral blood from patients with glioma

Correction to: Characterization of the first fully human anti-TEM1 scFv in models of solid tumor imaging and immunotoxin-based therapy

Clinical and immunologic evaluation of three metastatic melanoma patients treated with autologous melanoma-reactive TCR-transduced T cells

A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice

Cholecystokinin receptor antagonist alters pancreatic cancer microenvironment and increases efficacy of immune checkpoint antibody therapy in mice

Absolute lymphocyte counts at end of induction correlate with distinct immune cell compartments in pediatric B cell precursor acute lymphoblastic leukemia

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie